Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 14Recurrence 6Neoplasms 6Leukemia, Myeloid, Acute 6Prostatic Neoplasms 5Lymphoma, T-Cell, Cutaneous 4Neoplasms, Plasma Cell 3Lymphoma 3Leukemia 3Sezary Syndrome 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Thalassemia 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1

Interventions

Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Chromosome Aberrations × Panobinostat × Clear all
NCT01242774 2020-12-19

Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)

Novartis

Phase 1 Completed
46 enrolled
Other hematologic neoplasm

Chromosome Aberrations, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡